Search
34 result(s) for 'author#Jean Chastre' within BMC
Page 1 of 2
Sort by: Relevance | Date
-
Citation: Critical Care 2008 12(Suppl 2):P343
-
Abstract withdrawn
Citation: Critical Care 2008 12(Suppl 2):P506 -
Abstract withdrawn
Citation: Critical Care 2008 12(Suppl 2):P370 -
EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial
The potential interest of antifungal treatment of non-immunocompromized patients with sepsis, extra-digestive Candida colonization and multiple organ failure is unknown. It represents three-quarters of antifungal...
Citation: Trials 2013 14:399 -
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in prevent...
Citation: Critical Care 2022 26:355 -
Abstract withdrawn
Citation: Critical Care 2006 10(Suppl 1):P28 -
Abstract withdrawn
Citation: Critical Care 2006 10(Suppl 1):P13 -
Abstract withdrawn
Citation: Critical Care 2006 10(Suppl 1):P416 -
Abstract withdrawn
Citation: Critical Care 2007 11(Suppl 2):P231 -
Abstract withdrawn
Citation: Critical Care 2007 11(Suppl 2):P337 -
Abstract withdrawn
Citation: Critical Care 2007 11(Suppl 2):P483 -
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
The aim of this study was to compare a 7-day course of doripenem to a 10-day course of imipenem-cilastatin for ventilator-associated pneumonia (VAP) due to Gram-negative bacteria.
Citation: Critical Care 2012 16:R218 -
Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy
Ventilator-associated pneumonia (VAP) may contribute to the mortality associated with acute respiratory distress syndrome (ARDS). We aimed to determine the incidence, outcome, and risk factors of bacterial VAP...
Citation: Critical Care 2012 16:R65 -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
The incidence of nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus strains (MRSA) is on the rise worldwide. For years, vancomycin has been used as the drug of choice in the treatment of M...
Citation: European Journal of Medical Research 2010 15:507 -
Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]
Combination antibiotic therapy for ventilator associated pneumonia (VAP) is often used to broaden the spectrum of activity of empirical treatment. The relevance of such synergy is commonly supposed but poorly ...
Citation: Critical Care 2006 10:R52 -
Is bronchoalveolar lavage with quantitative cultures a useful tool for diagnosing ventilator-associated pneumonia?
The results of a recently published Canadian study suggest that bronchoalveolar lavage and endotracheal aspiration are associated with similar clinical outcomes and similar overall use of antibiotics in critic...
Citation: Critical Care 2007 11:123 -
Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials
Hospital-acquired and ventilator-associated pneumonia (HAP/VAP) are often selected for randomized clinical trials (RCTs) aiming at new drug approval. Guidelines for the design of such RCTs have been repeatedly...
Citation: Critical Care 2017 21:162 -
Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review
Bleeding is the most frequent complication in patients receiving venoarterial or venovenous extracorporeal membrane oxygenation (ECMO). Recombinant activated factor VII (rFVIIa) has been used in these patients...
Citation: Critical Care 2013 17:R55 -
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study
There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objectiv...
Citation: Critical Care 2019 23:371 -
Antibiotic stewardship in the intensive care unit
The rapid emergence and dissemination of antimicrobial-resistant microorganisms in ICUs worldwide constitute a problem of crisis dimensions. The root causes of this problem are multifactorial, but the core iss...
Citation: Critical Care 2014 18:480